Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanisms by which nevirapine increases HDL in HIV-positive subjects
2005-001372-12Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nevirapine in human immunodeficiency virus infection (HIV), sponsored by Boehringer Ingelheim. Primary endpoints: Percentage change in apo A-I FSR at 6 weeks and Mechanistic assessment of HDL increase. Started Jul 2005; status: completed.
02
Drugs
nevirapine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2005-001372-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001372-12.